Testing semaglutide's effect on heart energy in PAH
Part of Lungs & breathing clinical trials.
This study looks at how your heart uses energy when you have pulmonary arterial hypertension. It tests whether an existing diabetes medication can help improve your heart's fuel use, which may slow down the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of PAH (Group 1) from a right heart catheterization.
- You need to be between 18 and 85 years old.
- You must be on stable PAH medications for at least 3 months.
- You must qualify for semaglutide treatment based on weight/BMI criteria (BMI over 30, or over 27 with other conditions).
- You must be able to undergo an MRI (no pacemaker, metal implants, or severe claustrophobia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if the diabetes drug empagliflozin can help people with pulmonary arterial hypertension (PAH), a condition causing high blood pressure in the lungs. It aims to see if the drug improves symptoms and is safe for patients with moderate symptoms.
This study tests if a weekly injection (semaglutide) combined with an exercise program can help reduce fat stored in the heart and muscles in people with type 2 diabetes. It may improve how well your body handles sugar and lowers your risk for heart problems.
This trial tests how a new type of diabetes medicine, called a GLP-1 receptor agonist, affects heart artery health in people with type 2 diabetes who recently had a heart procedure. It aims to find out if adding this medicine can further protect the heart and improve recovery.
This study checks whether semaglutide is safe and feasible for people with advanced lung diseases and higher body weight. It may help by testing a structured treatment approach, but it includes several health and safety limits.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
This trial tests whether certain diabetes medications can help prevent worsening of heart disease in people who have prediabetes (higher than normal blood sugar, but not yet diabetes). It may be a good fit if you have known coronary artery disease and prediabetes.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.